Lantern Pharma Announces Issuance of New Patent that Strengthens Patent Portfolio for Cancer Drug Candidate LP-300

U.S. Patent No. 11,471,431 relates to the use of LP-300 to increase the survival time of patients with cancers overexpressing thioredoxin or glutaredoxin. The patent issuance extends commercial protection for uses of LP-300 until late 2032, increasing the potential for future partnering opportunities and the development of additional programs in specific cancer indications. Lantern has multiple additional pending patent applications relating to LP-300 and is continuing to file patent applications in this area.